NCT04209855: An ongoing trial by ImmunoGen, Inc.
This trial is ongoing. It must report results 3 weeks, 2 days ago.
Full data
Full entry on ClinicalTrials.gov | NCT04209855 |
---|---|
Title | MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression |
Results Status | Ongoing |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | Dec. 31, 2019 |
Completion date | Sept. 30, 2023 |
Required reporting date | Sept. 29, 2024, midnight |
Actual reporting date | None |
Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
Days late | None |